Santen, Arctic Vision sign deal for ARVN001 to treat UME [Yahoo! Finance]
Clearside Biomedical, Inc. (CLSD)
Last clearside biomedical, inc. earnings: 3/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.clearsidebio.com/investor-overview
Company Research
Source: Yahoo! Finance
The agreement grants Santen exclusive commercialisation rights in China, excluding Hong Kong, Macau and Taiwan. Arctic Vision will obtain up to $85m in upfront and milestone payments. The partnership aims to combine the strengths of both companies to serve UME patients and expand in the Chinese ophthalmology market. Santen Pharmaceutical chief operating officer and board director Rie Nakajima said: “Through this partnership with Arctic Vision, an ophthalmic biotech company that continues to pioneer new developments, we will be able to bring this potentially first reimbursable UME treatment to patients in China. “This partnership has the potential to create new opportunities for Santen to address unmet needs related to the posterior segment eye diseases in China.” ARVN001, formulated for administration into the suprachoroidal space, is a suspension of triamcinolone acetonide. Under the brand name XIPERE, it has been approved by the US Food and Drug Administration for UME tre
Show less
Read more
Impact Snapshot
Event Time:
CLSD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLSD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLSD alerts
High impacting Clearside Biomedical, Inc. news events
Weekly update
A roundup of the hottest topics
CLSD
News
- Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Landscape Research 2024 [Yahoo! Finance]Yahoo! Finance
- Clearside Biomedical, Inc. (NASDAQ: CLSD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.MarketBeat
- All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
CLSD
Earnings
- 11/12/24 - Beat
CLSD
Sec Filings
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- 11/4/24 - Form 4
- CLSD's page on the SEC website